A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers

Completed · Phase 1 · Has a placebo group

Conditions studied: Haemostasis, Healthy

In brief

This trial is conducted in the United States of America (USA). The aim of this trial is to determine the feasibility of demonstrating a quantifiable change from baseline in punch biopsy-induced bleeding durations and blood loss volumes in healthy subjects after receiving clopidogrel anti-platelet therapy.

Key facts

Study ID

NCT01603342

Run by

Novo Nordisk A/S

People needed

18

Starts

2007-12-01

Expected to finish

2008-01-01

Last updated by the study team

2016-11-25

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• PT within normal laboratory range

You may not qualify if…

• The receipt of any investigational drug within 1 month prior to this trial
• Use of anti-coagulation or anti-platelet therapy-defined as vitamin K antagonists, platelet antagonists, heparin (or low molecular weight heparin), aspirin or NSAIDs within 30 days prior to trial
• African-American race
• Weight above or equal to 160 kg
• Recent diagnosis of any illness that would be present concomitant to trial period

Where it is running

• Novo Nordisk Investigational Site — Neptune City, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.